Compare CBU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | AAPG |
|---|---|---|
| Founded | 1866 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | N/A | 2025 |
| Metric | CBU | AAPG |
|---|---|---|
| Price | $62.47 | $25.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $64.00 | $48.50 |
| AVG Volume (30 Days) | ★ 245.2K | 3.9K |
| Earning Date | 01-27-2026 | 03-26-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $796,942,000.00 | $54,524,554.00 |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $8.12 | $368.64 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $49.44 | $17.09 |
| 52 Week High | $68.11 | $48.45 |
| Indicator | CBU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 33.57 |
| Support Level | $59.61 | $25.52 |
| Resistance Level | $63.00 | $26.30 |
| Average True Range (ATR) | 1.62 | 0.57 |
| MACD | -0.06 | -0.12 |
| Stochastic Oscillator | 49.56 | 0.00 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.